ESTRO 2023 - Abstract Book

S1234

Digital Posters

ESTRO 2023

greater. Distribution of Gleason score 6, 7 and 8 or greater were 8.1%, 67.7% and 24%. Forty six percent of patients had positive margins. Median PSA of the entire cohort at the time of sRT was 0.27. Median PSA for group 1, 2 and 3 were 0.33, 0.26 and 0,2. Less than one third of patients of group 1 and 2 (26% and 32% respectively) had postoperative PSA of 0.2 ng/mL or less at the time of sRT. When analyzes were made between groups, only group 3 showed statistically significant differences in median PSA at the time of sRT compared to group 1 and group 2 (p<0.05). No differences were observed between group 1 and 2 (p=18).

Table 1

Figure 1 Median PSA for Group 1, Group 2 and Group 3

Conclusion RADICALS-RT demonstrated a significant impact on our clinical practice only after being supplemented with real local evidence. This information confirms the importance of real-world evidence complementing RCT in clinical practice. Clinician should be careful about adopting a sRT strategy if conditions are not appropriate. In this context, an aRT strategy should be revisited.

PO-1518 Stereotactic Body Radiation Therapy for adrenal metastases treated with Helical-Tomotherapy

J.M. Nieto-Guerrero Gomez 1 , M. Marti Laosa 1 , M.A. Gomez Aparicio 2 , E.M. Lozano Martin 2 , D. Carrasquilla de la Torre 1 , E. Jimenez Jimenez 1 1 Hospital General Universitario de Ciudad Real, Radiation Oncology, Ciudad Real, Spain; 2 Hospital Universitario de Toledo, Radiation Oncology, Toledo, Spain Purpose or Objective Stereotactic Body Radiation Therapy (SBRT) is a treatment option for patients with adrenal metastases. This study evaluated the impact and reported the tolerance of SBRT in adrenal metastases treated with Helical Tomotherapy at Radiation Oncology Department of Ciudad Real Hospital. Materials and Methods This is a single-center retrospective study of patients with adrenal metastases treated with SBRT between January 2017 and March 2022.